Skip to main content

Table 3 sRAGE in 200 COPD patients (univariate analysis)

From: Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study

Characteristics

n

Median

IQR

P-value

Smoking habits

    

Current smoker

97

677

483-1076

0.777

Former smoker

103

638

492-1063

 

Pack-years of smoking

    

>48

96

628

449-1055

0.479

≤48

104

669

484-1076

 

FEV 1 , % predicted

    

≥50

122

660

503-1078

0.015

<50

62

763

538-1138

 

<30

16

435

247-544

 

DL CO , % predicted

    

>76

96

745

546-1051

0.007

≤76

104

612

428-1076

 

Emphysema

    

No or mild

119

715

532-1174

0.003

Moderate

56

644

482-1041

 

Severe

25

465

243-644

 

Chronic cor pulmonale

    

yes

47

534

321-741

0.002

no

153

715

529-1164

 

Systemic arterial hypertension

    

yes

95

658

484-1064

0.999

no

105

644

477-1076

 

Coronary artery disease

    

yes

59

681

560-1040

0.352

no

141

631

465-1087

 

Heart failure

    

yes

23

886

583-1252

0.376

no

177

641

465-1039

 

Diabetes mellitus

    

yes

22

920

735-1123

0.003

no

178

630

475-1069

 

Dyslipidemia

    

yes

61

681

508-1078

0.539

no

139

631

480-1062

 

Inhaled corticosteroids

    

yes

128

642

482-1076

0.880

no

72

671

484-1078

 

Statins

    

yes

37

681

558-1033

0.713

no

163

641

470-1082

 
  1. Definitions of abbreviations: sRAGE = soluble receptor for advanced glycation end products (pg/mL); IQr = interquartile range. For the other abbreviations see table 1. The cutpoints of FEV1 % predicted are based on GOLD stage (see ref. [1]). The cutpoints for pack-years of smoking and DLCO % predicted are the median value in the whole sample.